61049-67-0

Basic information

• Product Name: 3-(benzyloxy)-4H-pyran-4-one
• Synonyms: 3-(benzyloxy)-4H-pyran-4-one
• CAS NO: 61049-67-0
• Molecular Formula: C₁₂H₁₀O₃
• Molecular Weight: 202.206
• Mol File: 61049-67-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 409.4°C at 760 mmHg
• Flash Point: 193.1°C
• Appearance: /
• Density: 1.21g/cm³
• Vapor Pressure: 6.53E-07mmHg at 25°C
• Refractive Index: 1.585
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-(benzyloxy)-4H-pyran-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(benzyloxy)-4H-pyran-4-one(61049-67-0)
• EPA Substance Registry System: 3-(benzyloxy)-4H-pyran-4-one(61049-67-0)

Safety Data

• Hazardous Substances Data: 61049-67-0(Hazardous Substances Data)

Usage

General Description

3-(Benzyloxy)-4H-pyran-4-one is a chemical compound that falls under the category of organic compounds known as benzyloxy compounds, specifically those comprising a benzyl group involved in an O-aryl bond to benzene. It is a pyranone, a class of organic molecules characterized by a pyran ring bearing a ketone. It exists as a light yellow crystalline powder and its molecular formula is C14H12O3. This chemical is generally utilized in different fields, particularly in the synthesis of various pharmaceutical products for its propitious medicinal properties like antioxidant, anti-microbial, anti-inflammatory, and anti-cancer traits. It can be produced synthetically and isn't naturally occurring. Regarding its safety, it should be utilized with caution as it can trigger skin, eye, and respiratory irritation on exposure.

InChI:InChI=1/C12H10O3/c13-11-6-7-14-12(8-11)15-9-10-4-2-1-3-5-10/h1-8H,9H2

Upstream product

• 1219-33-6 5-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid 
• 496-63-9 3-hydroxy-pyran-4-one 
• 100-39-0 benzyl bromide 
• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 
• 15771-06-9 5-benzyloxy-2-hydroxymethyl-4H-pyran-4-one 
• 100-44-7 benzyl chloride 

Downstream Products

• 362598-68-3 3-benzyloxy-1-(2-piperidin-1-yl-ethyl)-1H-pyridin-4-one 
• 362598-71-8 3-benzyloxy-1-(2-morpholin-4-yl-ethyl)-1H-pyridin-4-one 
• 362598-69-4 3-benzyloxy-1-(2-pyridin-2-yl-ethyl)-1H-pyridin-4-one 
• 362598-70-7 3-benzyloxy-1-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-1H-pyridin-4-one 
• 1064077-34-4 3-benzyloxy-1-methyl-1H-pyridin-4-one 
• 959327-48-1 3-benzyloxy-1-thiazolinomethyl-4(1H)-pyridone 
• 959676-13-2 3-benzyloxy-1-thiazolinoethyl-4(1H)-pyridone 
• 496-63-9 3-hydroxy-pyran-4-one 
• 1333331-84-2 3-[(4-methoxybenzyl)oxy]-4H-pyran-4-one 
• 1333331-85-3 3-[(4-methoxybenzyl)oxy]pyridin-4(1H)-one 
• 1333331-86-4 4'-iodo-3-[(4-methoxybenzyl)oxy]-4H-1,2'-bipyridin-4-one 
• 1333331-87-5 {3-[(4-methoxybenzyl)oxy]-4-oxo-4H-1,2'-bipyridin-4-yl}boronic acid 
• 1333331-88-6 3-[(4-methoxybenzyl)oxy]-4'-phenyl-[1,2']bipyridinyl-4-one 
• 1333331-89-7 6'-bromo-3-[(4-methoxybenzyl)oxy]-4H-1,2'-bipyridin-4-one 

Relevant articles and documents

Coumarin hybrid pyridinone amide derivative with potential anti-AD activity and preparation method and application of derivative

The invention discloses a coumarin hybrid pyridinone amide derivative and a preparation method and application thereof. The coumarin hybrid pyridinone amide derivative and pharmacologically acceptablesalt thereof are shown in the formula (I) and the formula (II), and the derivative can be used for preparing drugs for resisting the Alzheimer's disease, the Parkinson's disease or treating other diseases or symptoms by suppressing monoamine oxidase, chelating metallic iron ions, resisting A and resisting oxidation.

Systematic comparison of the mono-, dimethyl-and trimethyl 3-hydroxy-4(1H)-pyridones-Attempted optimization of the orally active iron chelator, deferiprone

A range of close analogues of deferiprone have been synthesised. The group includes mono-, di-and trimethyl-3-hydroxy-4(1H)-pyridones. These compounds were found to possess similar pFe3+ values to that of deferiprone, with the exception of the 2.5-dimethylated derivatives. Surprisingly the NHcontaining hydroxy-4(1H)-pyridones were found to be marginally more lipophilic than the corresponding N-Me containing analogues. This same group are also metabolised less efficiently by Phase 1 hydroxylating enzymes than the corresponding N-Me analogues. As result of this study, three compounds have been identified for further investigation centred on neutropenia and agranulocytosis.

Pyrones to pyrans: Enantioselective radical additions to acyloxy pyrones

This paper describes a highly site-, diastereo-, and enantioselective intermolecular radical addition/hydrogen atom transfer to hydroxypyrone pyromeconic and kojic acids. The methodology can be extended to the formation of chiral quaternary centers. The p